2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide nicotinic acetylcholine receptor ligands
申请人:AstraZeneca AB
公开号:US07491734B2
公开(公告)日:2009-02-17
Compounds of formula I:
wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
式子I的化合物:其中A,D,Ar1,E和Ar2的定义如规范中所述,制备它们的过程,含有它们的药物组合物以及它们在治疗中的应用,特别是在治疗或预防精神病和智力障碍方面的应用。